Literature DB >> 18327663

Two-tiered hypotheses for Duchenne muscular dystrophy.

M D Grounds1.   

Abstract

New approaches to understanding and designing treatments for Duchenne muscular dystrophy (DMD) may emerge from two hypotheses outlined here. The proposal that growing skeletal muscle is more susceptible to necrosis than adult muscle raises the possibility that less intensive treatments may be sufficient to protect muscles during the adult phase. The second proposal is that a different balance of cell and molecular events contributes to acute necrosis (e.g. resulting from exercise) compared with chronic damage of dystrophic muscle. Validation of such differences presents the potential for more specific targeting of drugs or nutritional interventions to events downstream of the dystrophin deficiency. A deeper understanding of the events arising as an early consequence of dystrophin deficiency in these two situations may strengthen approaches to therapy for DMD designed to improve muscle function and the quality of life.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18327663     DOI: 10.1007/s00018-008-7574-8

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  27 in total

1.  Dystrophin isoform induction in vivo by antisense-mediated alternative splicing.

Authors:  Sue Fletcher; Abbie M Adams; Russell D Johnsen; Kane Greer; Hong M Moulton; Steve D Wilton
Journal:  Mol Ther       Date:  2010-03-23       Impact factor: 11.454

2.  Increasing taurine intake and taurine synthesis improves skeletal muscle function in the mdx mouse model for Duchenne muscular dystrophy.

Authors:  Jessica R Terrill; Gavin J Pinniger; Jamie A Graves; Miranda D Grounds; Peter G Arthur
Journal:  J Physiol       Date:  2016-01-18       Impact factor: 5.182

Review 3.  High-content drug screening with engineered musculoskeletal tissues.

Authors:  Herman Vandenburgh
Journal:  Tissue Eng Part B Rev       Date:  2010-02       Impact factor: 6.389

4.  Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice.

Authors:  Raffaella Willmann; Annamaria De Luca; Michael Benatar; Miranda Grounds; Judith Dubach; Jean-Marc Raymackers; Kanneboyina Nagaraju
Journal:  Neuromuscul Disord       Date:  2011-07-06       Impact factor: 4.296

5.  In Vivo Viscoelastic Response (VisR) Ultrasound for Characterizing Mechanical Anisotropy in Lower-Limb Skeletal Muscles of Boys with and without Duchenne Muscular Dystrophy.

Authors:  Christopher J Moore; Melissa C Caughey; Diane O Meyer; Regina Emmett; Catherine Jacobs; Manisha Chopra; James F Howard; Caterina M Gallippi
Journal:  Ultrasound Med Biol       Date:  2018-08-31       Impact factor: 2.998

6.  An omega-3 fatty acid-enriched diet prevents skeletal muscle lesions in a hamster model of dystrophy.

Authors:  Roberta Fiaccavento; Felicia Carotenuto; Alba Vecchini; Luciano Binaglia; Giancarlo Forte; Enrico Capucci; Anna Maria Maccari; Marilena Minieri; Paolo Di Nardo
Journal:  Am J Pathol       Date:  2010-09-09       Impact factor: 4.307

7.  Dystrophin-deficient cardiomyocytes derived from human urine: new biologic reagents for drug discovery.

Authors:  Xuan Guan; David L Mack; Claudia M Moreno; Jennifer L Strande; Julie Mathieu; Yingai Shi; Chad D Markert; Zejing Wang; Guihua Liu; Michael W Lawlor; Emily C Moorefield; Tara N Jones; James A Fugate; Mark E Furth; Charles E Murry; Hannele Ruohola-Baker; Yuanyuan Zhang; Luis F Santana; Martin K Childers
Journal:  Stem Cell Res       Date:  2013-12-23       Impact factor: 2.020

Review 8.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

9.  Automated drug screening with contractile muscle tissue engineered from dystrophic myoblasts.

Authors:  Herman Vandenburgh; Janet Shansky; Frank Benesch-Lee; Kirsten Skelly; Janelle M Spinazzola; Yero Saponjian; Brian S Tseng
Journal:  FASEB J       Date:  2009-06-01       Impact factor: 5.191

10.  Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.

Authors:  Gavin J Pinniger; Jessica R Terrill; Evanna B Assan; Miranda D Grounds; Peter G Arthur
Journal:  J Physiol       Date:  2017-09-30       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.